<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266315</url>
  </required_header>
  <id_info>
    <org_study_id>REB16-2401</org_study_id>
    <nct_id>NCT03266315</nct_id>
  </id_info>
  <brief_title>Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery</brief_title>
  <acronym>ProPS</acronym>
  <official_title>Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital defects of the gastrointestinal tract commonly require surgical intervention in&#xD;
      the neonatal period. Intestinal surgery during this critical period of microbiome acquisition&#xD;
      results in aberrant colonization of the gastrointestinal tract by several pathways. Surgical&#xD;
      stress is known to cause disruption of the gut barrier and increase intestinal permeability&#xD;
      and bacterial translocation. This process triggers exaggerated immune responses that lead to&#xD;
      inflammation and sometimes infectious complications. Post-operative use of antibiotics has&#xD;
      been shown to potentiate the growth of pathogenic bacterial species Adults with abdominal&#xD;
      surgery who received post-op probiotics reported a significant reduction in surgical site&#xD;
      infection, urinary tract infection, and combined infection. Currently, probiotics used only&#xD;
      in the non-surgical population of infants.&#xD;
&#xD;
      The main objective of this study is to determine the impact of probiotics administration on&#xD;
      the intestinal microbiome in neonates undergoing intestinal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Objectives/Question:&#xD;
&#xD;
      The main objective of this study is to determine the impact of probiotics administration on&#xD;
      the intestinal microbiome in neonates undergoing gastrointestinal surgery.&#xD;
&#xD;
      Primary question:&#xD;
&#xD;
      Diversity and abundance of stool microbiome at after 1 and 3 weeks of initiation of&#xD;
      probiotics&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
      1. Length of hospital stay&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Study design This study will be a randomized controlled double-blinded trial in the NICU at&#xD;
      Alberta Children's Hospital. Probiotics or placebo will be administered orally or via naso-&#xD;
      or orogastric feeding tube. Intestinal microbiome data will be compared between the two&#xD;
      groups. The study duration will be 24 months.&#xD;
&#xD;
      Study Population Infants born between 23 - 41 weeks of gestation, admitted to NICU at Alberta&#xD;
      Children's Hospital for gastrointestinal surgery.&#xD;
&#xD;
        1. Inclusion Criteria:&#xD;
&#xD;
             1. Infants born between 23 - 41 weeks of gestation&#xD;
&#xD;
             2. Required gastrointestinal surgery in the first week of life (including spontaneous&#xD;
                intestinal perforation, bowel atresia, mechanical bowel obstruction, volvulus,&#xD;
                gastroschisis)&#xD;
&#xD;
             3. Ready to start enteral feeding&#xD;
&#xD;
        2. Exclusion Criteria:&#xD;
&#xD;
           1. Infants with major congenital anomalies excluding gastrointestinal tract 3.&#xD;
           Palliative care patients 4. Septic babies with positive blood, CSF or urine culture&#xD;
&#xD;
           Sample Size and feasibility:&#xD;
&#xD;
           Connivant sample of 20 patients (10 in each group)&#xD;
&#xD;
           Study protocol. Infants will be identified within 48 hours of surgery and parents will&#xD;
           be approached for informed consent. Once consent is obtained, subjects will be randomly&#xD;
           assigned to receive either probiotics or placebo. Investigators will conduct the&#xD;
           randomization using a computer-generated table of random numbers generated at the&#xD;
           University of Calgary.&#xD;
&#xD;
           Preparation and Administration of Study Drug The study supplementation will be started&#xD;
           at the when oral feeds will reach 24 mL/kg/day after surgery after collecting a&#xD;
           stool/ostomy sample. The decision to start feeding will be made by the neonatal and&#xD;
           surgical team. After the first stool/ostomy sample is obtained, one study sachet to a&#xD;
           minimum of 1 mL of Expressed Breast Milk (EBM) (mothers own milk or donor human milk)&#xD;
           once a day.&#xD;
&#xD;
           Placebo sachet will be made of 0.3 g maltodextrin and be administered to the control&#xD;
           group in the same manner. If the infant is placed NPO, the study drug will be stopped&#xD;
           and restarted together with refeeding. Both probiotics and placebo will be packaged as a&#xD;
           single-dose sachet. The study probiotic/placebo will be given till discharge. If the&#xD;
           infant is transferred outside NICU, the study drug will be dispensed with the infant and&#xD;
           clinical outcomes will be ascertained in collaboration with the local Pediatrician at&#xD;
           the time of infants' discharge home.&#xD;
&#xD;
           Sample collection Nurses will collect the stool samples at 3-time points: prior to&#xD;
           initiation, 1 week after and 3 weeks after probiotic or placebo administration is&#xD;
           commenced. &quot;Stool&quot; will be collected directly from the infant's ostomy bag and diaper&#xD;
           with a sterile spatula. As soon as a sample is collected, the nurse will contact the&#xD;
           investigators. The samples will then be placed in a laboratory freezer (-80Â°C) within 24&#xD;
           hours of collection. Batched samples will be transported to the University of Calgary&#xD;
           Genomics laboratory for subsequent microbiome processing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal microbiome</measure>
    <time_frame>3 weeks after surgury</time_frame>
    <description>Stool microbiome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>6 months</time_frame>
    <description>Time between birth and hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Probiotics</condition>
  <condition>Infant, Newborn</condition>
  <condition>Surgical Procedures, Operative</condition>
  <condition>Gastro-Intestinal Disorder</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be randomly assigned to receive FloraBaby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will be randomly assigned to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FloraBaby</intervention_name>
    <description>1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants born between 23 - 41 weeks of gestation&#xD;
&#xD;
          2. Required gastrointestinal surgery (including spontaneous intestinal perforation, bowel&#xD;
             atresia, mechanical bowel obstruction, volvulus, gastroschisis)&#xD;
&#xD;
          3. Ready to start enteral feeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infants with major congenital anomalies excluding gastrointestinal tract&#xD;
&#xD;
          2. Palliative care patients&#xD;
&#xD;
        4. Septic babies with positive blood, CSF or urine culture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alixe N Howlett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belal N AlShaikh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alixe Howlett, MD</last_name>
    <phone>4039557442</phone>
    <email>alixe.howlett@ahs.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belal N Alshaikh, MD</last_name>
    <phone>403 956 1588</phone>
    <email>balshaik@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belal M ALshaikh, MD</last_name>
      <phone>4039561588</phone>
      <email>balshaik@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alixe M Howlett, MD</last_name>
      <email>alixe.howlett@ahs.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Belal M Alshaikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Alixe Howlett</investigator_full_name>
    <investigator_title>Clinical Associate Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

